Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Molecular oncology [Mol Oncol] NLMUID: 101308230"" wg kryterium: JN


Tytuł :
Cyr61 from adipose-derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin α V β 5 .
Autorzy :
Liang Z; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Bioland Laboratory, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.
Liu H; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Bioland Laboratory, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.
Zhang Y; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Xiong L; Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zeng Z; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
He X; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Wang F; State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Wu X; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Bioland Laboratory, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.
Lan P; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Bioland Laboratory, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 17. Date of Electronic Publication: 2021 May 17.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.
Autorzy :
Moura DS; Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013, Seville, Spain.
Peña-Chilet M; Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013, Seville, Spain.; Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio. 41013. Seville, Spain.; Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, 41013, Seville, Spain.
Cordero Varela JA; Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013, Seville, Spain.
Alvarez-Alegret R; Pathology department, Miguel Servet university hospital, Zaragoza, Spain.
Agra-Pujol C; Pathology department, Gregorio Marañon universitary hospital, Madrid, Spain.
Izquierdo F; Pathological anatomy service, Complejo Asistencial Universitario de León, Leon, Spain.
Ramos R; Pathology department, Son Espases university hospital, Mallorca.
Ortega-Medina L; Pathology department, Hospital clinico San Carlos, Madrid, Spain.
Martin-Davila F; Pathology department, Ciudad Real general hospital, Ciudad Real, Spain.
Castilla-Ramirez C; Pathology department, University hospital Virgen del Rocio, Seville, Spain.
Hernandez-Leon CN; Pathology department, Canarias university hospital, Santa Cruz de Tenerife, Spain.
Romagosa C; Pathology department, Vall d'Hebron university hospital, Barcelona, Spain.
Vaz Salgado MA; Medical oncology department, Cajal University Hospital, Madrid, Spain.
Lavernia J; Medical oncology department, Instituto Valenciano de oncologia, Valencia, Spain.
Bagué S; Pathology service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Mayodormo-Aranda E; Pathology department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
Vicioso L; Pathology department, Virgen de la Victoria university hospital, Malaga, Spain.
Barceló JEH; Pathology department, Virgen de la Arrixaca universitary hospital, Murcia, Spain.
Rubio-Casadevall J; Medical Oncology Department, Hospital Josep Trueta, Catalan Institute of Oncology, Girona, Spain.
de Juan A; Medical oncology department, Marqués de Valdecilla universitary hospital, Santander, Spain.
Fiaño-Valverde MC; Department of Histopathology, Álvaro Cunqueiro Hospital, University Hospital Complex Of Vigo, Vigo, Spain.
Hindi N; Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013, Seville, Spain.; Medical Oncology department, University Hospital Fundación Jimenez Diaz.; University Hospital General de Villalba.; Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD).
Lopez-Alvarez M; Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013, Seville, Spain.
Lacerenza S; Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013, Seville, Spain.
Dopazo J; Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013, Seville, Spain.; Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio. 41013. Seville, Spain.; Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, 41013, Seville, Spain.; INB-ELIXIR-es, FPS, Hospital Virgen del Rocío, Seville, 42013, Spain.
Gutierrez A; Hematology department, Son Espases university hospital, Mallorca, Spain.
Alvarez R; Medical oncology department, Gregorio Marañon universitary hospital, Madrid, Spain.
Valverde C; Medical oncology department, Vall d'Hebron university hospital, Barcelona, Spain.
Martinez-Trufero J; Medical oncology department, Miguel Servet university hospital, Zaragoza, Spain.
Martín-Broto J; Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013, Seville, Spain.; Medical Oncology department, University Hospital Fundación Jimenez Diaz.; University Hospital General de Villalba.; Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD).
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 13. Date of Electronic Publication: 2021 May 13.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion.
Autorzy :
Jobe NP; Experimental Pathology, Department of Translational Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Åsberg L; Experimental Pathology, Department of Translational Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Andersson T; Experimental Pathology, Department of Translational Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 09. Date of Electronic Publication: 2021 May 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Novel CTRP8-RXFP1-JAK3-STAT3 axis promotes Cdc42-dependent actin remodeling for enhanced filopodia formation and motility in human glioblastoma cells.
Autorzy :
Glogowska A; Depts. of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada.
Thanasupawat T; Depts. of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada.
Beiko J; Surgery, University of Manitoba, Winnipeg, Canada.
Pitz M; Research Institute in Oncology and Hematology (RIOH), CancerCare Manitoba, University of Manitoba, Winnipeg, Canada.
Hombach-Klonisch S; Depts. of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada.; Research Institute in Oncology and Hematology (RIOH), CancerCare Manitoba, University of Manitoba, Winnipeg, Canada.
Klonisch T; Depts. of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada.; Surgery, University of Manitoba, Winnipeg, Canada.; Research Institute in Oncology and Hematology (RIOH), CancerCare Manitoba, University of Manitoba, Winnipeg, Canada.; Medical Microbiology & Infectious Diseases, University of Manitoba, Winnipeg, Canada.; Rady Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Canada.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 07. Date of Electronic Publication: 2021 May 07.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
CDX2 expression in the hematopoietic lineage promotes leukemogenesis via TGFβ inhibition.
Autorzy :
Galland A; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.
Gourain V; Karlsruhe Institute of Technology, Institute of Biological and Chemical Systems, 76021, Karlsruhe, Germany.
Habbas K; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.
Güler Y; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.
Martin E; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.
Ebel C; Université de Strasbourg, Inserm, IGBMC / UMR-S 1258, 67404, Illkirch, France.
Tavian M; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.
Vallat L; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.; Centre Hospitalier Universitaire de Strasbourg, Laboratoire d'Hématologie, Strasbourg, France.
Chenard MP; Centre Hospitalier Universitaire de Strasbourg, Département de Pathologie, Strasbourg, France.
Mauvieux L; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.; Centre Hospitalier Universitaire de Strasbourg, Laboratoire d'Hématologie, Strasbourg, France.
Freund JN; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.
Duluc I; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.
Domon-Dell C; Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, 67200, Strasbourg, France.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 06. Date of Electronic Publication: 2021 May 06.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Tspan5 promotes epithelial-mesenchymal transition and tumour metastasis of hepatocellular carcinoma by activating Notch signalling.
Autorzy :
Xie Q; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Guo H; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
He P; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Deng H; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Gao Y; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Dong N; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Niu W; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Liu T; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Li M; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Wang S; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Wu Y; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Li JL; Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.; Wenzhou Medical University Eye Hospital and School of Biomedical Engineering, Wenzhou, 325027, China.; Cancer Research Centre, University of Chinese Academy of Sciences Wenzhou Institute, Wenzhou, 325001, China.; Institute of Translational and Stratified Medicine, University of Plymouth Faculty of Medicine and Dentistry, Plymouth, PL6 8BU, U.K.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 05. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention.
Autorzy :
Dias MH; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 05. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative EGFR profiling in vesicular-RNA.
Autorzy :
Pasini L; Bioscience Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)'Dino Amadori', Meldola, Italy.
Notarangelo M; Laboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
Vagheggini A; Unit of Biostatistics, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)'Dino Amadori', Meldola, Italy.
Burgio MA; Medical Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)'Dino Amadori', Meldola, Italy.
Crinò L; Medical Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)'Dino Amadori', Meldola, Italy.
Chiadini E; Bioscience Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)'Dino Amadori', Meldola, Italy.
Prochowski A; Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori', Meldola, Italy.
Delmonte A; Medical Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)'Dino Amadori', Meldola, Italy.
Ulivi P; Bioscience Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)'Dino Amadori', Meldola, Italy.
D'Agostino VG; Laboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 03. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Bispecific antibodies come to the aid of cancer immunotherapy.
Autorzy :
Amelio I; Department of Experimental Medicine, University of Rome Tor Vergata, TOR, Rome, Italy.; School of Life Sciences, University of Nottingham, Nottingham, UK.
Melino G; Department of Experimental Medicine, University of Rome Tor Vergata, TOR, Rome, Italy.
Levine AJ; Institute for Advanced Study, Simons Center for Systems Biology, Princeton, NJ, USA.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 03. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook.
Autorzy :
Lianidou E; Analysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Greece.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 03. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Systematic analysis of migration factors by MigExpress identifies essential cell migration control genes in non-small cell lung cancer.
Autorzy :
Pal J; Division of Cancer Research, Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) - Partner Site Freiburg, Germany.
Becker AC; Division of Cancer Research, Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) - Partner Site Freiburg, Germany.
Dhamija S; Division of Cancer Research, Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) - Partner Site Freiburg, Germany.; Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; CSIR Institute of Genomics and Integrative Biology, New Delhi, India.
Seiler J; Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abdelkarim M; Division of Cancer Research, Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) - Partner Site Freiburg, Germany.
Sharma Y; Division of Cancer Research, Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) - Partner Site Freiburg, Germany.
Behr J; Leibniz Institute for Food Systems, Technical University of Munich, Freising, Germany.; Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), Technical University of Munich, Freising, Germany.
Meng C; Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), Technical University of Munich, Freising, Germany.
Ludwig C; Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), Technical University of Munich, Freising, Germany.
Kuster B; Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), Technical University of Munich, Freising, Germany.; Chair of Proteomics and Bioanalytics, DKTK Partner Site Munich, Freising, Germany.
Diederichs S; Division of Cancer Research, Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) - Partner Site Freiburg, Germany.; Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 02. Date of Electronic Publication: 2021 May 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Autorzy :
Pastor B; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.
Thierry A; Sorbonne University, Department of Medical Oncology, Saint-Antoine University Hospital, Paris, France.; Oncology Multidisciplinary Research Group (GERCOR), Paris, France.
Henriques J; Methodology and Quality of Life Unit in Oncology, Besançon University Hospital, Besançon, France.
Trouilloud I; Sorbonne University, Department of Medical Oncology, Saint-Antoine University Hospital, Paris, France.; Oncology Multidisciplinary Research Group (GERCOR), Paris, France.
Tournigand C; Oncology Multidisciplinary Research Group (GERCOR), Paris, France.; Medical Oncology Service, Henri Mondor Hospital, AP-HP, Université Paris Est Créteil Créteil, France.
Marine J; Oncology Multidisciplinary Research Group (GERCOR), Paris, France.; Bourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; Department of Medical Oncology, Besançon University Hospital, Besançon, France.
Mazard T; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.; Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier, France.
Louvet C; Oncology Multidisciplinary Research Group (GERCOR), Paris, France.; Department of Medical Oncology, Institut Monsouris, Paris, France.
Azan S; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.
Bauer A; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.
Roch B; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.; Department of Thoracic Oncology, Montpellier University Hospital, Université de Montpellier, Montpellier, France.
Sanchez C; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.
Vernerey D; Oncology Multidisciplinary Research Group (GERCOR), Paris, France.; Methodology and Quality of Life Unit in Oncology, Besançon University Hospital, Besançon, France.
Thierry AR; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.; Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier, France.
Adenis A; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Montpellier Cancer Institute (ICM), Montpellier, France.; Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier, France.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 02. Date of Electronic Publication: 2021 May 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
Autorzy :
Yang JY; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Huo YM; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yang MW; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Shen Y; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Liu DJ; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Fu XL; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Tao LY; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
He RZ; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhang JF; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Hua R; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jiang SH; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, China.
Sun YW; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Liu W; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 01. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors.
Autorzy :
Li J; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wang Y; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Li L; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Or PM; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wai Wong C; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Liu T; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Ho WLH; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Chan AM; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 01. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
SENP3 loss promotes M2 macrophage polarization and breast cancer progression.
Autorzy :
Xiao M; Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Bian Q; Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Lao Y; Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yi J; Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Sun X; Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Sun X; Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yang J; Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 01. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Protease-activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma.
Autorzy :
Tekin C; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands.; Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands.
Scicluna BP; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands.
Lodestijn SC; Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands.
Shi K; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands.
Bijlsma MF; Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands.
Spek CA; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands.; Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 01. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer.
Autorzy :
Gao X; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liang J; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang L; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Zhang Z; Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, College of Basic Medicine, Hubei University of Medicine, Shiyan, China.
Yuan P; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang J; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Gao Y; Department of Orthopaedic Surgery, The Second Affiliated Hospital, Chongqing Medical University, China.
Ma F; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Calagua C; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ye H; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Department of Pathology, University of California Los Angeles, CA, USA.
Voznesensky O; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Wang S; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang T; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu J; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chen S; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Liu X; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 01. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Platycodin D inhibits autophagy and increases glioblastoma cell death via LDLR upregulation.
Autorzy :
Lee SJ; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Korea.; Center for Cognition and Sociality, Institute for Basic Science, Daejeon, Korea.
Choi YJ; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Korea.
Kim HI; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Korea.
Moon HE; Department of Neurosurgery, Advanced Institute of Convergence Technology (AICT), Cancer Research Institute, and Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Korea.
Paek SH; Department of Neurosurgery, Advanced Institute of Convergence Technology (AICT), Cancer Research Institute, and Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Korea.
Kim TY; Center for Cognition and Sociality, Institute for Basic Science, Daejeon, Korea.; Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Korea.
Ko SG; Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Korea.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 01. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
Autorzy :
Sreekumar R; Cancer Sciences Division, University of Southampton, UK.
Al-Saihati H; Cancer Sciences Division, University of Southampton, UK.; College of Applied Medical Sciences, University of Hafr Al-Batin, Saudi Arabia.
Emaduddin M; Cancer Sciences Division, University of Southampton, UK.
Moutasim K; Cancer Sciences Division, University of Southampton, UK.
Mellone M; Cancer Sciences Division, University of Southampton, UK.
Patel A; Cancer Sciences Division, University of Southampton, UK.
Kilic S; Cancer Sciences Division, University of Southampton, UK.
Cetin M; Department of Molecular Biology and Genetics, Gebze Technical University, Turkey.
Erdemir S; Department of Molecular Biology and Genetics, Gebze Technical University, Turkey.
Navio MS; Cancer Sciences Division, University of Southampton, UK.
Lopez MA; Cancer Sciences Division, University of Southampton, UK.
Curtis N; Department of Surgery, Southampton University Hospital NHS Trust, UK.
Yagci T; Department of Molecular Biology and Genetics, Gebze Technical University, Turkey.
Primrose JN; Cancer Sciences Division, University of Southampton, UK.; Department of Surgery, Southampton University Hospital NHS Trust, UK.
Price BD; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Berx G; Molecular Cellular Oncology Lab, Department for Biomedical Molecular Biology, Ghent University, Belgium.; Cancer Research Institute Ghent (CRIG), Belgium.
Thomas GJ; Cancer Sciences Division, University of Southampton, UK.
Tulchinsky E; Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan.
Mirnezami A; Cancer Sciences Division, University of Southampton, UK.; College of Applied Medical Sciences, University of Hafr Al-Batin, Saudi Arabia.
Sayan AE; Cancer Sciences Division, University of Southampton, UK.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 01. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.
Autorzy :
Sultan M; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.
Nearing JT; Departments of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
Brown JM; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.
Huynh TT; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.
Cruickshank BM; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.
Lamoureaux E; Departments of Pharmacology, Dalhousie University, Halifax, NS, Canada.
Vidovic D; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.
Dahn ML; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.
Fernando W; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.
Coyle KM; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.
Giacomantonio CA; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.; Departments of Surgery, Dalhousie University, Halifax, NS, Canada.
Langille MG; Departments of Pharmacology, Dalhousie University, Halifax, NS, Canada.
Marcato P; Departments of Pathology, Dalhousie University, Halifax, NS, Canada.; Departments of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 May 01. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies